Treace Medical (TMCI) Q1 2026 earnings review
Volume Growth Fails to Mask Severe Revenue Contraction
Treace Medical’s transition to a 'comprehensive bunion solutions' company is heavily cannibalizing its top line. While management claims case volumes are growing, the market shift toward their lower-priced minimally invasive (MIS) products drove a painful 10% YoY revenue contraction in Q1. The volume swap is proving costly: Net Loss widened to $18.0 million and Adjusted EBITDA deteriorated. The only structural bright spot is aggressive operating expense control, which management is using to protect the balance sheet until newly launched TAM-expanding products potentially restore growth in the back half of the year.
🐂 Bull Case
Total operating expenses dropped by $2.9M YoY in Q1. The company is successfully leveraging past investments to drastically reduce cash burn, aiming for a ~50% reduction in cash usage for FY26.
The initiation of the limited market release for the SuperBite Compression Screw marks the company's first move into adjacent foot and ankle markets, aiming to unlock an estimated $300M in incremental TAM.
🐻 Bear Case
Revenue fell 10% despite 'growing year-over-year case volumes.' This indicates that lower-ASP products (like Nanoplasty and Percuplasty) are heavily cannibalizing the higher-priced, core Lapiplasty franchise.
The combination of top-line contraction and a slight dip in gross margin (79.3% vs 79.7%) caused Net Loss to widen to $18.0M from $15.9M a year ago, raising questions about the company's ultimate path to profitability.
⚖️ Verdict: 🔴
Bearish. Selling more volume for less total revenue is a losing game. Until management can prove that MIS product adoption is truly additive rather than strictly cannibalistic to Lapiplasty, the top-line trajectory remains fundamentally impaired.
Key Themes
Cannibalization Disguised as Market Share Gains
Management stated they 'continued to take market share and grow year-over-year case volumes.' However, this positive narrative directly contradicts the financial reality: revenue declined 10% YoY. By introducing lower-ASP MIS osteotomy products to capture the 70% of the market that resists Lapiplasty fusions, the company is actively cannibalizing its own high-margin core. Volume growth is destroying value if it comes at a steeply discounted ASP.
Strict Operating Expense Control
Management is aggressively managing the P&L to survive the top-line contraction. Total operating expenses fell to $54.6M in 26Q1 from $57.5M a year ago. Sales and marketing expenses absorbed the bulk of the cuts, dropping to $33.8M from $36.1M. If Treace can return to revenue growth in H2 as guided, this leaner cost structure will create significant operating leverage.
SuperBite System Unlocks New TAM
Treace initiated the limited market release of the SuperBite Compression Screw System, marking a critical transition. Moving beyond pure bunion correction, this technology explicitly targets broader mid-foot and hind-foot procedures, which management previously noted represents approximately $300 million in incremental addressable market.
Persistent Macro Headwinds in Elective Surgeries
The foot and ankle market remains under pressure. In previous quarters, management acknowledged that softer consumer sentiment and macroeconomic uncertainty were leading to deferrals in elective bunion procedures. The current Q1 results and negative FY26 revenue guidance confirm that these headwinds have not abated.
Gross Margin Creeping Downward
Gross margin contracted slightly to 79.3% in 26Q1 from 79.7% in 25Q1. While still robust, the combination of lower ASPs from the shifting product mix and inflationary manufacturing pressures suggests that peak pricing power is likely in the rearview mirror.
Other KPIs
Reversing negatively compared to the $6.2M profit posted in 25Q4, and worsening from the $(3.8)M loss in 25Q1. The drop in top-line revenue directly flowed through to the bottom line, nullifying the $2.9M reduction in operating expenses.
Cash, cash equivalents, and marketable securities increased sequentially by $3.5M from Q4 2025. Supported by an available $115M credit facility, the balance sheet remains adequate to weather the current revenue transition, assuming management successfully halves cash burn this year.
Guidance
Reversing. The midpoint ($207M) implies a -2.7% YoY contraction compared to FY25's $212.7M. Management expects to return to stronger growth in the back half of the year, implying that Q2 will remain under severe pressure as the company continues to lap tough comps and negative mix shifts.
Stable. The midpoint $(5.0)M loss is roughly in line with the $3.9M loss generated in FY25. This indicates management plans to offset the gross profit dollars lost to revenue contraction entirely through OPEX cuts.
Accelerating improvement. Following a reported 46% decrease in cash usage in 2025, a further 50% cut demonstrates severe capital discipline, likely driven by structural reductions in CapEx and marketing spend.
Key Questions
ASP Gap and Mix Stabilization
Given the 10% revenue decline despite volume growth, exactly what is the Average Selling Price (ASP) gap between Lapiplasty and the new MIS osteotomy systems? When do you model this mix shift bottoming out?
Sales Compensation Structure
With the rapid uptake of lower-priced products, how are sales representatives incentivized? Are compensation plans aligned to protect high-ASP Lapiplasty volumes, or are reps inadvertently encouraged to push cheaper kits for volume quotas?
Back-Half Growth Visibility
You are guiding for a return to stronger growth in the back half of 2026. Aside from easier comps, what specific leading indicators (like training lab bookings or SuperBite initial orders) give you confidence in this inflection?